Brand-name Drugmaker Tactic ‘Product Hopping’ Costs US Healthcare System $4.7 Billion Annually, Study Says
Brand-name Drugmaker Tactic ‘Product Hopping’ Costs US Healthcare System $4.7 Billion Annually, Study Says Maia Anderson | Becker’s Hospital Review “An anti-competitive tactic used by brand-name drugmakers called product hopping costs the U.S....
New Report Shows Brand Drug Product Hopping Costs Billions for Patients and Healthcare System Each Year
New Report Shows Brand Drug Product Hopping Costs Billions for Patients and Healthcare System Each Year Alex Brill | Washington, DC Today, Matrix Global Advisors (MGA) released a new report, “The Cost of Brand Drug Product Hopping,” commissioned by the Coalition for...- MGA Releases Economic Impact Report for Multinational Pharmaceutical Company
- ‘The Price of Business’: Discussing Today’s Political and Economic Environment
- New MGA Report Presents Biosimilar Market Opportunities in Ophthalmology
- Alex Brill to FTC: Claims That PBMs Raise Drug Prices are Unfounded
- Do Tax Cuts Cause Inflation? Alex Brill on ‘The Price of Business’
- ‘The Price of Business’: Alex Brill Talks Rising Inflation
- Massachusetts’s Proposed ‘Millionaires’ Tax’ Will Push up the Federal Deficit
- Charitable Giving is Good. Be Smart About how to Encourage It.
- MGA Report Cited in Forbes Article on Rising Prescription Drug Prices
- New Report from MGA Examines Impact of Rebates on Drug Pricing, Competition
